Research Article

Chronic Pain Prevalence and Exposures during Pregnancy

Shona L. Ray-Griffith,1,2 Bethany Morrison,3 and Zachary N. Stowe4

1Department of Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, USA
2Department of Obstetrics & Gynecology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
3College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA
4Department of Psychiatry, University of Wisconsin at Madison, Madison, WI, USA

Correspondence should be addressed to Shona L. Ray-Griffith; slray@uams.edu

Received 8 May 2019; Accepted 15 July 2019; Published 8 August 2019

Academic Editor: Till Sprenger

Copyright © 2019 Shona L. Ray-Griffith et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pregnant women with chronic pain present a unique clinical challenge for both chronic pain and obstetrical providers, and clinical guidelines do not exist. The present study describes the prevalence and management of chronic pain during pregnancy in a perinatal mood disorder clinic. A retrospective chart review of pregnant women who presented to the Women’s Mental Health Program at the University of Arkansas for Medical Sciences (UAMS) for an initial evaluation from July 2013 to June 2016 was conducted to obtain demographic and medical information, including pharmacological exposures. Data are described using the mean and standard deviation for continuous data and frequency for categorical data. Pain complaints and medications are presented as counts and percentages. Differences between women with and without chronic pain were assessed by t-tests for continuous variables and chi-square analysis for categorical variables. Of the 156 pregnant women, chronic pain conditions were reported by 44 (28.2%). The most common chronic pain complaints included neck and/or back pain (34.1%) and headaches (31.8%). Of subjects with chronic pain, 95.5% were taking at least one prescription medication (mean ± 2.6, range of 0–10). Acetaminophen (43.2%) and opioids (43.2%) were the most common. The complexity of managing maternal benefits of treatment with the risks of fetal exposures presents a uniquely challenging clinical scenario for healthcare providers.

1. Introduction

In 2011, the Institute of Medicine released a report on pain estimating that 100 million adults in the United States live with chronic pain conditions [1]. Physical and mental functioning, quality of life, and professional and personal relationships are negatively affected by chronic pain. Moreover, societal stigma around chronic pain and risks associated with the long-term use of pain medications, such as opioids, exacerbates these problems. Women, in comparison with men, experience a greater burden of disease and functional disability as well as lower therapeutic effects with long-term opioid use [2–4]. The perinatal period presents a particularly vulnerable state for women with chronic pain disorders, and data supporting the prevalence, course, and management of perinatal chronic pain disorders are scarce [5]. Chronic pain and obstetrical providers encounter a complex clinical situation where maternal benefits of treatment must be effectively balanced with the risks of maternal illness and fetal exposure to both treatment and maternal illness.

Treatment options for chronic pain disorders during the perinatal period include both pharmacological and nonpharmacological options (e.g., physical therapy); however, uncertainties around treatment impact both the patient and the provider’s medical decision-making. For example, among a sample of pregnant women with low back pain, only 32% discussed these symptoms with their prenatal care providers, and 75% of providers did not make any recommendations to manage symptoms [6]. Many women also discontinue pharmacological options immediately upon knowledge of conception due to fears of teratogenic potential.

Another concerning factor includes the limited and discordant reproductive safety data on pharmacological treatments for chronic pain [7]. For example, acetaminophen
is a first-line analgesic for pregnant women as it does not produce classic teratogenic effects. However, recent studies have associated perinatal acetaminophen exposure with an increased risk for attention-deficit/hyperkinetic, respiratory, autism spectrum, and testicular disorders in children [8–17]. Opioids are another example as 14–22% of women fill an opioid prescription during pregnancy [18, 19] despite potential adverse neonatal outcomes [20–24]. Moreover, available data support the use of amitriptyline and/or nortriptyline as first-line agents for both nociceptive and neuropathic pain during pregnancy [25–27]; however, use in nonpregnant populations is limited by underutilization by prescribers [28] and patient intolerability [29]. Potential adverse obstetrical and/or neonatal complications are associated with maternal use of NSAIDs and venlafaxine [30], and the use of pregabalin and duloxetine is limited by insufficient reproductive safety data [31]. Notably, antiepileptic exposure in pregnancy is more common for the treatment of pain than epilepsy [32–34]. However, reproductive safety data of antiepileptic drugs are derived from women with epilepsy as well as mood and pain disorders with the majority of studies being confounded by polypharmacy [33–37].

Collectively, reproductive safety data indicate a high potential for adverse outcomes associated with the most commonly used pharmacological treatments for chronic pain, which supports almost exclusive recommendations to use nonpharmacological treatments (e.g., physical therapy and massage). Unfortunately, access to these options may be limited, ineffective, and/or unaffordable. With limited available data to support medical decision-making in women with chronic pain disorders during pregnancy, treatment optimization may depend on reducing concurrent medication exposures, maintaining the minimal effective dose, and decreasing additional exposures associated with risk.

Chronic pain disorders frequently co-occur with mental illness. For example, rates of depression in individuals with chronic pain are twice as high of those without chronic pain [38]—a difference more impactful when comparing women and men [39, 40]. Psychiatrists are often involved in the treatment of individuals with chronic pain given the high rates of comorbid mental illness. Thus, reproductive psychiatrists may find themselves as part of the team managing pregnant patients with chronic low back pain, depression, and fibromyalgia, to name a few. The first step in establishing evidence-based guidelines for the management of chronic pain during the perinatal period is to establish the severity and acuity of the problem. In the present study, we sought to determine the prevalence and assess prepregnancy medication use and adverse outcomes associated with chronic pain during pregnancy in a university-based perinatal mood disorder clinic.

2. Materials and Methods

A retrospective chart review of all pregnant women who presented to the Women’s Mental Health Program (WMHP) at the University of Arkansas for Medical Sciences (UAMS) for an initial evaluation from July 1, 2013, to June 30, 2016, was conducted. The WMHP is an academic mental health program specializing in the treatment of neuropsychiatric illnesses during the perinatal period. The referral base of the WMHP includes psychiatric and obstetrical practices within UAMS and the community throughout Arkansas as well as self-referral. For the current study, subjects were excluded if they were not currently pregnant (i.e., postpartum or preconception), less than 18 years of age, and/or did not consent to having their information used for clinical research investigation at their initial visit. Information was obtained from written and electronic medical records and included demographic information, medical and surgical history (including obstetrical and psychiatric), medication use, and other exposures.

Demographic and obstetrical data are described using the mean and standard deviation for continuous data and frequency for categorical data. Missing data were not included in the total. Differences between groups were assessed by t-tests for continuous variables and by chi-square analysis for categorical variables. Chronic pain complaints and current medications are presented as counts and percentages. A p value of <0.05 was considered statistically significant. Data were analyzed using Sigma Plot 12.5.

This study was approved by the institutional review board at UAMS.

3. Results

A total of 222 pregnant women presented to the WMHP at UAMS for an initial evaluation. Of which, 66 respondents declined participation in research. This resulted in 156 participants for the current analysis. Chronic pain conditions were reported by more than a quarter of respondents (n = 44, 28.2%). Table 1 displays the demographic characteristics of respondents, including by the presence or absence of chronic pain complaints. No differences were found between the groups.

Among respondents with chronic pain, the most common complaints included neck and/or back pain, headaches, and “other” pain complaints (e.g., pelvic and abdominal pain, neuropathic pain, and fibromyalgia). 95.5% (n = 42) were currently taking at least one prescription medication, and 59.5% (n = 26) were taking two or more medications.

Table 2 lists all medications reported by respondents with chronic pain. The mean number of medications taken was 2.6 ± 1.1 with a range between 0 and 10. More than 20% (n = 10) of subjects with chronic pain were concomitantly taking an opioid and benzodiazepine. Nonpharmacological therapy, including physical therapy and transcutaneous electrical nerve stimulation, was reported by 20.5% (n = 32).

4. Discussion

The literature on chronic pain among pregnant women is limited, and this study aimed at determining the prevalence and prepregnancy examination of chronic pain during pregnancy in a university-based perinatal mood disorder clinic. A chronic pain condition was self-reported by 28.2%
of initial evaluations, and the two most common complaints were neck and/or back pain and headaches. The majority were taking more than one medication at initial presentation with nearly half taking acetaminophen and/or opioids. Nonpharmacological therapy was less common contributing in less than one-quarter of respondents.

With high rates of comorbid pain in people with depression [41, 42], it was not surprising that our study found more than a quarter of patients presenting to a perinatal mood disorder clinic had a comorbid chronic pain condition. Previous studies of chronic prescription opioid use among pregnant women for pain management also identify headaches/migraine and back pain as the most frequent complaints [18, 43]. Although the rate of chronic pain conditions during pregnancy is lower than those in the general population, the authors believe it warrants the need for awareness among chronic pain physicians as well as obstetrical providers. The national opioid epidemic has raised awareness of the complexity of patients with chronic pain disorders, chronic opioid treatment, and opioid use disorders. As a result, providers should be aware of the Center for Disease Control and Prevention (CDC) guidelines for the management of chronic pain disorders [44] as well as the American College of Obstetrics and Gynecology guidelines for the management of opioid use disorder during pregnancy [45].

Our previous work has shown that less than a quarter of reproductive-aged women with long-term opioid prescriptions fill prescriptions for contraceptives [46]. The study population had an unplanned pregnancy rate of 69.5%.

| Demographics                          | All (n = 156) | Chronic pain complaint | p-value |
|---------------------------------------|--------------|------------------------|---------|
|                                       |              | Yes (n = 44)           | No (n = 112) |       |
| Age (years ± SD)                      | 28.3 ± 5.5   | 29.1 ± 4.8             | 27.9 ± 5.8   | 0.205  |
| Education (years ± SD)                | 14.3 ± 2.4   | 14.2 ± 2.1             | 14.3 ± 2.5   | 0.606  |
| Race/ethnicity (%)                    |              |                        |            |       |
| White                                 | 126 (80.8)   | 38 (86.4)              | 88 (78.6)   | 0.376  |
| Nonwhite                              | 30 (19.2)    | 6 (13.6)               | 24 (21.4)   |         |
| Marital status (%)                    |              |                        |            |       |
| Married                               | 78 (50.0)    | 20 (45.5)              | 58 (51.2)   | 0.594  |
| Not married                           | 78 (50.0)    | 24 (54.5)              | 54 (48.2)   |         |
| Medical comorbidity* (%)              |              |                        |            |       |
| Yes                                   | 50 (32.1)    | 14 (31.8)              | 36 (32.1)   | 0.880  |
| No                                    | 106 (67.9)   | 30 (68.2)              | 76 (67.9)   |         |
| Self-reported history of physical, emotional, or sexual abuse (%) | | | | |
| Yes                                   | 94 (61.0)    | 29 (65.9)              | 65 (59.1)   | 0.548  |
| No                                    | 60 (39.0)    | 15 (34.1)              | 45 (40.9)   |         |
| Tobacco use (%)                       |              |                        |            |       |
| None                                  | 69 (44.2)    | 21 (47.7)              | 48 (42.9)   | 0.520  |
| Current use                           | 42 (26.9)    | 9 (20.5)               | 33 (29.5)   |         |
| History of use                        | 45 (28.8)    | 14 (31.8)              | 31 (27.7)   |         |
| Alcohol use (%)                       |              |                        |            |       |
| None                                  | 62 (39.7)    | 19 (43.2)              | 43 (38.4)   | 0.652  |
| Current use                           | 2 (1.3)      | 1 (2.2)                | 1 (0.9)     |         |
| History of use                        | 92 (59.0)    | 24 (54.5)              | 68 (60.7)   |         |
| Self-reported illicit drug use (%)    |              |                        |            |       |
| None                                  | 81 (51.9)    | 25 (56.8)              | 56 (50.0)   | 0.383  |
| Current use                           | 15 (9.6)     | 2 (4.5)                | 13 (11.6)   |         |
| History of use                        | 60 (38.5)    | 17 (38.6)              | 43 (38.4)   |         |
| Obstetrical information               |              |                        |            |       |
| Severity (number ± SD)                | 2.8 ± 1.8    | 3.1 ± 1.9              | 2.7 ± 1.7   | 0.139  |
| Parity (number ± SD)                  | 1.1 ± 1.2    | 1.4 ± 1.3              | 1.0 ± 1.1   | 0.083  |
| Gestational age (weeks ± SD)          | 21.2 ± 8.8   | 21.2 ± 9.5             | 20.3 ± 8.5  | 0.620  |
| Trimester at initial evaluation (%)   |              |                        |            |       |
| 1st                                   | 48 (31.0)    | 14 (31.8)              | 34 (30.6)   | 0.138  |
| 2nd                                   | 66 (42.6)    | 14 (31.8)              | 52 (46.8)   |         |
| 3rd                                   | 41 (26.5)    | 16 (36.4)              | 25 (22.5)   |         |
| Planned pregnancy (%)                 |              |                        |            |       |
| Yes                                   | 46 (30.5)    | 11 (25.6)              | 35 (32.4)   | 0.531  |
| No                                    | 105 (69.5)   | 32 (74.4)              | 73 (67.6)   |         |
| Desired pregnancy (%)                 |              |                        |            |       |
| Yes                                   | 76 (50.3)    | 22 (51.2)              | 54 (50.0)   | 0.870  |
| No                                    | 15 (9.9)     | 5 (11.6)               | 10 (9.3)    |         |
| Mixed feelings                        | 60 (39.7)    | 16 (37.2)              | 44 (40.7)   |         |

*Medical comorbidities include hypertension, diabetes, asthma, and thyroid conditions.
Given the rate of unplanned pregnancies in the general United States population is nearly 50% [47], women with chronic pain disorders may have an unmet need for family planning. The CDC recently published guidelines for the prescription of opioids for chronic pain, and recommendations include a discussion of family planning with the initial prescription of opioids [44]. This discussion should include family planning as well as the adverse obstetrical and fetal risks associated with pharmacological and non-pharmacological treatment options. If an unintended pregnancy does occur, a realistic goal is the development of a treatment plan at the earliest possible gestational age to maximize the benefit-to-risk ratio.

Primary fetal development occurs in the first trimester (i.e., up to 14 weeks of gestation), and exposures during that time may pose a risk. In this study, pregnant women presented at about 21 weeks of gestation or during the second trimester—past the first trimester. Moreover, the overwhelming majority of women were taking at least one analgesic medication. Notably, up to 10 pharmacological agents were reported in isolated cases. Application of known reproductive safety data is difficult in patients with chronic pain disorders as the impact of polypharmacy on perinatal outcomes is understudied.

Acetaminophen and opioids were the most commonly used agents—a finding that raises numerous questions. First, are these patients receiving optimal care for chronic pain conditions prior to knowledge of pregnancy? First-line pharmacological options for chronic pain include acetaminophen, nonsteroidal anti-inflammatory drugs, topical agents, tricyclic antidepressants, selective norepinephrine reuptake inhibitors, and gabapentinoids [48–52], while opioids are last-line treatment options. Second, the reproductive safety data of acetaminophen have recently been questioned [8, 9, 11, 15, 16, 53, 54]. Moreover, clinical experience raises concerns of appropriate dosing of acetaminophen as patients often report exceeding recommended dosage instructions and are given sparse guidance from healthcare professionals regarding dosing and presence of acetaminophen in preparations of over-the-counter and prescription medications. Third, the specific risks of opioids for chronic pain syndromes during the perinatal period are unknown. Data concerning obstetrical and neonatal outcomes with opioid exposure in utero are often derived from addiction studies and may not be directly applicable to pain disorder management [55]. Lastly, the epidemic of prescription opioid use in the United States population has extended to pregnant women and is of concern secondary to the adverse effects opioids have on maternal and neonatal health [19, 56, 57]. Comparable to this study, previous studies support an increasing trend of opioid use among pregnant women [19, 56, 57]. Changing physiology in pregnancy may require increased daily opiate dose [58], and prenatal exposure may exceed six months. Both duration of

| Table 2: Medication exposures among pregnant women with chronic pain disorders. |
|---------------------------------|---------------|-----------------|
| Medication class               | N (%)         | Individual medications |
|--------------------------------|---------------|-------------------------|
| Opioids                        | 19 (43.2)     | Buprenorphine 1 (2.3)  |
|                                |               | Fentanyl 1 (2.3)       |
|                                |               | Hydrocodone 13 (29.5)  |
|                                |               | Oxycodone 6 (13.6)     |
|                                |               | Tramadol 4 (9.1)       |
| Acetaminophen                  | 19 (43.2)     | Acetaminophen 19 (43.2) |
|                                |               | Alprazolam 6 (13.6)    |
|                                |               | Clonazepam 3 (6.8)     |
| Sedative/hypnotic              | 16 (36.4)     | Diazepam 5 (11.4)      |
|                                |               | Lorazepam 1 (2.3)      |
|                                |               | Zolpidem 6 (13.6)      |
|                                |               | Gabapentin 6 (13.6)    |
| Antiepileptic drugs            | 13 (29.5)     | Lamotrigine 4 (9.1)    |
|                                |               | Pregabalin 1 (2.3)     |
|                                |               | Topiramate 2 (4.5)     |
|                                |               | Carisoprodol 3 (6.8)   |
| Muscle relaxant                | 7 (15.9)      | Cyclobenzaprine 3 (6.8) |
|                                |               | Methocarbamol 1 (2.3)  |
| Steroid                       | 7 (15.9)      | Steroid 7 (15.9)       |
|                                |               | Etodolac 1 (2.3)       |
| Nonsteroidal anti-inflammatory drugs | 3 (6.8) | Ibuprofen 1 (2.3)       |
|                                |               | Naproxen 1 (2.3)       |
| Selective serotonin reuptake inhibitors | 11 (25.0) | Citalopram 2 (4.5)     |
|                                |               | Escitalopram 2 (4.5)   |
|                                |               | Fluoxetine 5 (11.4)    |
|                                |               | Sertraline 2 (4.5)     |
| Selective norepinephrine reuptake inhibitors | 5 (11.4) | Desvenlafaxine 1 (2.3) |
|                                |               | Venlafaxine 4 (9.1)    |
| Tricyclic antidepressants      | 1 (2.3)       | Doxepin 1 (2.3)        |
| Norprenorphine reuptake inhibitor | 1 (2.3) | Bupropion 1 (2.3)      |
use and dose escalation are associated with increased risk of addiction [59, 60].

Only 20.5% of respondents utilized nonpharmacological treatments. Possible explanations for low utilization of nonpharmacological therapies include a lack of access, efficacy, reproductive safety data, and/or inadequate insurance coverage. Our study did not identify rates of cognitive-behavioral therapy use for chronic pain disorders, but cognitive-behavioral therapy is an effective treatment that should be considered for both chronic pain conditions and many psychiatric disorders in the perinatal period.

The current study has limitations warranting consideration. The population is derived from a specialty clinic and may not be generalizable to populations without psychiatric illnesses. Data were primarily collected from self-reported intake forms and are subject to recall bias. Although self-reported measures have been found to be a strong indicator of pain and a patient’s psychosocial profile [61], they are only part of the clinical picture and must be used in conjunction with valid observation-based assessment tools in order to accurately evaluate patients. Finally, this was a retrospective chart review in a clinic focused on neuropsychiatric disorders during the perinatal period, and reports of chronic pain disorders may be underreported as the extent of inquiry by providers may have varied.

5. Conclusion

Chronic pain conditions among pregnant women with psychiatric illness are common and likely confer a significant burden of disease to both mother and fetus. The complexity of managing maternal benefits of treatment with the risks of fetal exposures presents a uniquely challenging clinical scenario for both chronic pain and obstetrical providers. Current guidelines for the management of chronic pain emphasize the importance of multimodal approaches, and progress towards effective and safe chronic pain management in pregnancy will require a multidisciplinary, biopsychosocial approach. Future research should examine both independent and dependent effects of pain and its treatment on perinatal outcomes in neuropsychiatric populations.

Data Availability

The clinical data used to support the findings of this study have not been made available due to patient privacy.

Disclosure

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health.

Conflicts of Interest

Dr. Ray-Griffith currently receives clinical trial support from Neuronetics and has received clinical trial support from Sage Therapeutics. She has never served on a speaker’s bureau or advisory board. Neither she nor her family members have every held equity positions in biomedical or pharmaceutical corporations. Dr. Stowe has received research support from Eli Lilly, Glaxo SmithKline (GSK), Janssen, Sage Therapeutics, the National Institutes of Health (NIH), and Wyeth. He has served on speakers’ bureaus and/or received honoraria from Eli Lilly, GSK, Pfizer, and Wyeth. He has served on advisory boards for GSK and BSM. Neither he nor family members have ever held equity positions in biomedical or pharmaceutical corporations. Ms. Morris declares that she has no competing financial interests.

Acknowledgments

Dr. Ray’s work was supported by the University of Arkansas for Medical Sciences Translational Research Institute (Grants UL1TR000039 and KL2TR000063) through the National Institute of Health, National Center for Research Resources, and the National Center for Advancing Translational Sciences and T32 DA022981-06. Ms. Morrison’s work was supported by T32 DA022981/DA/NIDA HIH HHS (2T32DA022981-06).

References

[1] L. S. Simon, “Relieving pain in America: a blueprint for transforming prevention, care, education, and research,” Journal of Pain & Palliative Care Pharmacotherapy, vol. 26, no. 2, pp. 197-198, 2012.
[2] B. D. Darnall and B. R. Stacey, “Sex differences in long-term opioid use,” Archives of Internal Medicine, vol. 172, no. 5, pp. 431-432, 2012.
[3] K. Amris, E. E. Wæhrens, A. Jespersen, H. Bliddal, and B. Danneskiold-Samsøe, “Observation-based assessment of functional ability in patients with chronic widespread pain: a cross-sectional study,” Pain, vol. 152, no. 11, pp. 2470-2476, 2011.
[4] L. LeResche, K. Saunders, S. Dublin et al., “Sex and age differences in global pain status among patients using opioids long term for chronic noncancer pain,” Journal of Women’s Health, vol. 24, no. 8, pp. 629-635, 2015.
[5] S. Ray-Griffith, M. Wendel, Z. Stowe, and E. Magann, “Chronic pain during pregnancy: a review of the literature,” International Journal of Women’s Health, vol. 10, pp. 153–164, 2018.
[6] S.-M. Wang, P. Dezimno, I. Maranets, M. R. Berman, A. A. Caldwell-Andrews, and Z. N. Kain, “Low back pain during pregnancy,” Obstetrics & Gynecology, vol. 104, no. 1, pp. 65–70, 2004.
[7] F. Coluzzi, H. Valensise, M. Sacco, and M. Allegri, “Chronic pain management in pregnancy and lactation,” Minerva Anestesiologica, vol. 80, no. 2, pp. 211–224, 2014.
[8] Z. Liew, B. Ritz, C. Rebordosa, P.-C. Lee, and J. Olsen, “Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disorders,” JAMA Pediatrics, vol. 168, no. 4, pp. 313–320, 2014.
[9] Z. Liew, B. Ritz, J. Virk, and J. Olsen, “Maternal use of acetaminophen during pregnancy and risk of autism spectrum disorders in childhood: a Danish national birth cohort study,” Autism Research, vol. 9, no. 9, pp. 951–958, 2016.
[10] E. Bakkeheim, P. Mowinckel, K. H. Carlsen, G. Håland, and K. C. L. Carlsen, “Paracetamol in early infancy: the risk of childhood allergy and asthma,” Acta Paediatrica, vol. 100, no. 1, pp. 90–96, 2011.
network of teratological information services (ENTIS)," Reproductive Toxicology, vol. 10, no. 4, pp. 285–294, 1996.

[27] C. Vasilakis-Scaroomaza, A. Aschengrau, H. Cabral, and S. S. Jick, "Antidepressant use during early pregnancy and the risk of congenital anomalies," Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol. 33, no. 7, pp. 693–700, 2013.

[28] C. Reed, H. G. Birnbaun, J. I. Ivanoa et al., "Real-world role of tricyclic antidepressants in the treatment of fibromyalgia," Pain Practice, vol. 12, no. 7, pp. 533–540, 2012.

[29] W.-Q. Liu, A. Kanungo, and C. Toth, "Equivalency of tricyclic antidepressants in open-label neuropathic pain study," Acta Neurologica Scandinavica, vol. 129, no. 2, pp. 132–141, 2014.

[30] G. G. Briggs, R. K. Freeman, and S. J. Yaffe, Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, Lippincott Williams & Wilkins, Philadelphia, PA, U.S.A, 2012.

[31] S. L. Hoog, Y. Cheng, J. Elpers, and S. A. Dowsett, "Duloxetine and pregnancy outcomes: safety surveillance findings," International Journal of Medical Sciences, vol. 10, no. 4, pp. 413–419, 2013.

[32] W. V. Bobo, R. L. Davis, S. Toh et al., "Trends in the use of antiepileptic drugs among pregnant women in the US, 2001–2007: a medication exposure in pregnancy risk evaluation program study," Paediatric and Perinatal Epidemiology, vol. 26, no. 6, pp. 578–588, 2012.

[33] H. Fujii, A. Goel, N. Bernard et al., "Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study," Neurology, vol. 80, no. 17, pp. 1565–1570, 2013.

[34] U. Winterfeld, P. Merlob, D. Baud et al., "Pregnancy outcome following maternal exposure to pregabalin may call for concern," Neurology, vol. 86, no. 24, pp. 2251–2257, 2016.

[35] C. Chambers, K. K. Kao, R. J. Feket et al., "Pregnancy outcome in infants prenatally exposed to newer anticonvulsants," Birth Defects Research Part A: Clinical and Molecular Teratology, vol. 73, p. 316, 2005.

[36] J. Morrow, A. Russell, E. Guthrie et al., "Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK epilepsy and pregnancy register," Journal of Neurology, Neurosurgery & Psychiatry, vol. 77, no. 2, pp. 193–198, 2006.

[37] S. Hunt, A. Russell, W. H. Smithson et al., "Topiramate in pregnancy: preliminary experience from the UK epilepsy and pregnancy register," Neurology, vol. 71, no. 4, pp. 272–276, 2008.

[38] M. Meana, R. Cho, and M. DesMeules, "Chronic pain: the extra burden on Canadian women," BMC Women's Health, vol. 4, no. 1, p. S17, 2004.

[39] S. E. P. Munce and D. E. Stewart, "Gender differences in depression and chronic pain conditions in a national epidemiologic survey," Psychosomatics, vol. 48, no. 5, pp. 394–399, 2007.

[40] L. Calvó-Pérezas, J. Vilalta-Branch, O. Turró-Garriga, S. López-Pousa, and J. Garre-Olmo, "Gender differences in depression and pain: a two year follow-up study of the survey of health, ageing and retirement in Europe," Journal of Affective Disorders, vol. 193, pp. 157–164, 2016.

[41] M. J. Bair, R. L. Robinson, W. Katon, and K. Kroenke, "Depression and pain comorbidity," Archives of Internal Medicine, vol. 163, no. 20, pp. 2433–2445, 2003.

[42] P. G. Lindsay and M. Wyckoff, "The depression-pain syndrome and its response to antidepressants," Psychosomatics, vol. 22, no. 7, pp. 571–577, 1981.

[43] A. Kellogg, C. H. Rose, R. H. Harms, and W. J. Watson, "Current trends in narcotic use in pregnancy and neonatal outcomes," American Journal of Obstetrics and Gynecology, vol. 204, no. 3, pp. 259.e1–259.e4, 2011.
[44] D. Dowell, T. M. Haegerich, and R. Chou, “CDC guideline for prescribing opioids for chronic pain—United States, 2016,” JAMA, vol. 315, no. 15, pp. 1624–1645, 2016.

[45] Committee on Obstetric Practice, “Committee opinion no. 711: opioid use and opioid use disorder in pregnancy,” Obstetrics & Gynecology, vol. 130, no. 2, pp. e81–e94, 2017.

[46] S. L. Ray-Griffith, D. Chopra, Z. N. Stowe, and B. C. Martin, “Claims for contraceptive services among young women filling chronic opioid prescriptions,” Contraception, vol. 99, no. 5, pp. 296–299, 2019.

[47] L. B. Finer and M. R. Zolna, “Unintended pregnancy in the United States: incidence and disparities, 2006,” Contraception, vol. 84, no. 5, pp. 478–485, 2011.

[48] R. Chou, G. J. Fanciullo, P. G. Fine et al., “Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain,” The American Journal of Medicine, vol. 122, no. 10, pp. S22–S32, 2009.

[49] T. K. Nuckols, L. Anderson, I. Popescu et al., “Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain,” Annals of Internal Medicine, vol. 160, no. 1, pp. 38–47, 2014.

[50] D. E. Moulin, A. J. Clark, I. Gilron et al., “Pharmacological management of chronic neuropathic pain—consensus statement and guidelines from the Canadian pain society,” Pain Research and Management, vol. 12, no. 1, pp. 13–21, 2007.

[51] A. B. O’Connor and R. H. Dworkin, “Treatment of neuropathic pain: an overview of recent guidelines,” The American Journal of Medicine, vol. 122, no. 10, pp. S22–S32, 2009.

[52] N. Attal, G. Cruccu, R. Baron et al., “EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision,” European Journal of Neurology, vol. 17, no. 9, pp. 1113–e88, 2010.

[53] O. Becquet, D. Bonnet, Y. Ville, K. Allegaert, and A. Lapillonne, “Paracetamol/acetaminophen during pregnancy induces prenatal ductus arteriosus closure,” Pediatrics, vol. 142, no. 1, article e20174021, 2018.

[54] E. Ystrom, K. Gustavsson, R. E. Brandlistuen et al., “Prenatal exposure to acetaminophen and risk of ADHD,” Pediatrics, vol. 140, no. 5, article e20163840, 2017.

[55] H. E. Jones, C. J. Friedman, J. J. Starer, M. Terplan, and S. Gitlow, “Opioid use during pregnancy,” Addictive Disorders & Their Treatment, vol. 13, no. 1, pp. 8–15, 2014.

[56] R. A. Epstein, W. V. Bobo, P. R. Martin et al., “Increasing pregnancy-related use of prescribed opioid analgesics,” Annals of Epidemiology, vol. 23, no. 8, pp. 498–503, 2013.

[57] A. A. Mitchell, S. M. Gilboa, M. M. Werler, K. E. Kelley, C. Louik, and S. Hernández-Díaz, “Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008,” American Journal of Obstetrics and Gynecology, vol. 205, no. 1, pp. 51.e1–51.e8, 2011.

[58] D. L. Bogen, J. M. Perel, J. C. Helsel et al., “Pharmacologic evidence to support clinical decision making for peripartum methadone treatment,” Psychopharmacology, vol. 225, no. 2, pp. 441–451, 2013.

[59] A. Alam, T. Gomes, and H. Zheng, “Long-term analgesic use after low-risk surgery,” Archives of Internal Medicine, vol. 172, no. 5, pp. 425–430, 2012.

[60] P. V. Piazza and V. Deroche-Gamonet, “A multistep general theory of transition to addiction,” Psychopharmacology, vol. 229, no. 3, pp. 387–413, 2013.

[61] K. Amris, E. Wæhrens, A. Stockmarr, H. Bliddal, and B. Danneskiold-Samsøe, “Factors influencing observed and self-reported functional ability in women with chronic widespread pain: a cross-sectional study,” Journal of Rehabilitation Medicine, vol. 46, no. 10, pp. 1014–1021, 2014.